Single‐Dose Pharmacokinetics of Oral and Intravenous Pantoprazole in Children and Adolescents

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Journal of clinical pharmacology

• Publication date

  2008-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/0091270008321811PMID 18664620
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Characteristics of children receiving proton pump inhibitors continuously for up to 11 years duration.

  2007cited by this paper
• Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem.

  2006cited by this paper
• Pharmacokinetics of Proton Pump Inhibitors in Children

  2005cited by this paper
• Pharmacogenetics and pharmacogenomics.

  2005cited by this paper
• Omeprazole Disposition in Children following Single‐Dose Administration

  2003cited by this paper
• Pharmacokinetics of IV Pantoprazole in Pediatric Patients

  2003cited by this paper
• Proton Pump Inhibitors in Pediatrics: Relevant Pharmacokinetics and Pharmacodynamics

  2003cited by this paper
• Overview of Pediatric Gastroesophageal Reflux Disease and Proton Pump Inhibitor Therapy

  2003cited by this paper
• Developmental pharmacology--drug disposition, action, and therapy in infants and children.

  2003cited by this paper
• The Natural Course of Gastroesophageal Reflux Disease in Children

  2002cited by this paper
• Pharmacokinetic‐pharmacodynamic study of oral lansoprazole in children

  2002cited by this paper
• Stereoselective pharmacokinetics of pantoprazole, a proton pump inhibitor, in extensive and poor metabolizers of S‐mephenytoin

  2001cited by this paper
• Pharmacogenetics and pharmacogenomics.

  2001cited by this paper
• Pharmacokinetics of orally administered omeprazole in children

  2000cited by this paper
• Selection of Drugs to Treat Gastro-Oesophageal Reflux Disease

  2000cited by this paper
• Pharmacokinetics and metabolism of the proton pump inhibitor pantoprazole in man.

  1999cited by this paper
• A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin.

  1999cited by this paper
• Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin.

  1998cited by this paper
• One-year follow-up of symptoms of gastroesophageal reflux during infancy. Pediatric Practice Research Group.

  1998cited by this paper
• A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin.

  1998cited by this paper
• An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians.

  1998cited by this paper
• One-Year Follow-up of Symptoms of Gastroesophageal Reflux During Infancy

  1998cited by this paper
• Developmental expression of CYP2C and CYP2C-dependent activities in the human liver: in-vivo/in-vitro correlation and inducibility.

  1997cited by this paper
• Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele.

  1997cited by this paper
• Lack of pantoprazole drug interactions in man: an updated review.

  1996cited by this paper
• Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs

  1996cited by this paper
• Direct determination of pantoprazole enantiomers in human serum by reversed-phase high-performance liquid chromatography using a cellulose-based chiral stationary phase and column-switching system as a sample cleanup procedure.

  1996cited by this paper
• Pharmacokinetics of pantoprazole in man.

  1996cited by this paper
• Lack of pantoprazole drug interactions in man: an updated review.

  1996cited by this paper
• Pharmacokinetics, Metabolism and Interactions of Acid Pump Inhibitors

  1996cited by this paper
• Pharmacokinetics of pantoprazole in man.

  1996cited by this paper
• Genetic tests which identify the principal defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism.

  1996cited by this paper
• The continuing development of proton pump inhibitors with particular reference to pantoprazole

  1995cited by this paper
• The interaction of proton pump inhibitors with cytochromes P450.

  1994cited by this paper
• Gastroesophageal Reflux in the Older Child: Presentation, Response to Treatment and Long-Term Follow-Up

  1991cited by this paper

• Pharmacokinetics and safety of intravenous pantoprazole in a hospitalized pediatric population.

  2025cites this paper
• Relationship between CYP2C19 genotypes and proton pump inhibitorsʹs pharmacokinetics and pharmacodynamics: review

  2024cites this paper
• Pharmacogenetic Aspects of Drug Metabolizing Enzymes and Transporters in Pediatric Medicine: Study Progress, Clinical Practice and Future Perspectives

  2023influential citation
• Perspectives from the Society for Pediatric Research: Pharmacogenetics for Pediatricians

  2021cites this paper
• New Guidance on Cytochrome P450 2C19 Phenotype-based Use of Proton Pump Inhibitors

  2021cites this paper
• Development and validation of high-performance liquid chromatography method for the simultaneous monitoring of pantoprazole sodium sesquihydrate and domperidone maleate in plasma and its application to pharmacokinetic study

  2020cites this paper
• Gene-Based Dose Optimization in Children.

  2020cites this paper
• Gradient HPLC-DAD method for quantification of novel oral anticoagulant "Edoxaban" in plasma: Its selective determination in presence of sixteen co-administered drugs.

  2020cites this paper
• Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing

  2020cites this paper
• Raft-forming system for pantoprazole and domperidone delivery: in vitro and in vivo study

  2019cites this paper
• CYP2C19 Phenotype and Risk of Proton Pump Inhibitor–Associated Infections

  2019cites this paper
• Development and pharmacokinetic evaluation of alginate-pectin polymeric rafts forming tablets using box behnken design

  2018influential citation
• Pantoprazole, an Inhibitor of the Organic Cation Transporter 2, Does Not Ameliorate Cisplatin‐Related Ototoxicity or Nephrotoxicity in Children and Adolescents with Newly Diagnosed Osteosarcoma Treated with Methotrexate, Doxorubicin, and Cisplatin

  2018cites this paper
• Obese Children Require Lower Doses of Pantoprazole Than Nonobese Peers to Achieve Equal Systemic Drug Exposures

  2018cites this paper
• A Population-Based Pharmacokinetic Model Approach to Pantoprazole Dosing for Obese Children and Adolescents

  2018cites this paper
• Novel Implementation of Genotype‐Guided Proton Pump Inhibitor Medication Therapy in Children: A Pilot, Randomized, Multisite Pragmatic Trial

  2018cites this paper
• Assessing CYP2C19 Ontogeny in Neonates and Infants Using Physiologically Based Pharmacokinetic Models: Impact of Enzyme Maturation Versus Inhibition

  2018influential citation
• Pediatric intensive care stress ulcer prevention (PIC-UP): a protocol for a pilot randomized trial

  2017cites this paper
• Clinical Pharmacogenetics of Cytochrome P450-Associated Drugs in Children

  2017cites this paper
• Meta‐analysis of hepatic cytochrome P450 ontogeny to underwrite the prediction of pediatric pharmacokinetics using physiologically based pharmacokinetic modeling

  2016cites this paper
• Proton Pump Inhibitors in Pediatrics

  2013cites this paper
• Pediatric perspective on pharmacogenomics.

  2013cites this paper
• Phase I, multicenter, randomized, open-label study evaluating the pharmacokinetics and safety profile of repeated once-daily doses of intravenous esomeprazole in children 0 to 17 years of age.

  2012cites this paper
• Oral pantoprazole-induced acute pancreatitis in an 11-year-old child.

  2012cites this paper
• Review of pantoprazole in pediatrics

  2011cites this paper
• Proton pump inhibitors in pediatrics: evaluation of efficacy in GERD therapy.

  2011cites this paper
• A Multicenter, Randomized, Open‐Label, Pharmacokinetics and Safety Study of Pantoprazole Tablets in Children and Adolescents Aged 6 Through 16 Years With Gastroesophageal Reflux Disease

  2011cites this paper
• Pharmacokinetics and Tolerability of Rabeprazole in Children 1 to 11 Years Old With Gastroesophageal Reflux Disease

  2011cites this paper
• Drug Evaluation Review of pantoprazole in pediatrics

  2011cites this paper
• Population Pharmacokinetic Modeling of Pantoprazole in Pediatric Patients From Birth to 16 Years

  2011cites this paper
• Innovative clinical trial design for pediatric therapeutics

  2011cites this paper
• Randomized, Open-Label, Multicentre Pharmacokinetic Studies of Two Dose Levels of Pantoprazole Granules in Infants and Children Aged 1 Month through <6 Years with Gastro-Oesophageal Reflux Disease

  2011cites this paper
• Short Communication Impact of the CYP2C19*17 Allele on the Pharmacokinetics of Omeprazole and Pantoprazole in Children: Evidence for a Differential Effect

  2010cites this paper
• Single-dose, multiple-dose, and population pharmacokinetics of pantoprazole in neonates and preterm infants with a clinical diagnosis of gastroesophageal reflux disease (GERD)

  2010cites this paper
• MECHANISMS OF VARIABILITY IN CYP2D6 METABOLISM: THE CONTRIBUTIONS OF POLYMORPHISMS, COPY NUMBER VARIATIONS AND microRNA

  2010cites this paper
• Impact of the CYP2C19*17 Allele on the Pharmacokinetics of Omeprazole and Pantoprazole in Children: Evidence for a Differential Effect

  2010influential citation
• Pantoprazole

  2009cites this paper
• PEDIATRIC PHARMACOTHERAPY A Monthly Newsletter for Health Care Professionals from the University of Virginia Children ’ s Hospital Volume 15 Number 3 March 2009 Advances in Pediatric Pharmacokinetics

  2009cites this paper